AMORPHOUS, EOSINOPHILIC, AND ACELLULAR DEPOSIT

Clinical trials for AMORPHOUS, EOSINOPHILIC, AND ACELLULAR DEPOSIT explained in plain language.

Never miss a new study

Get alerted when new AMORPHOUS, EOSINOPHILIC, AND ACELLULAR DEPOSIT trials appear

Sign up with your email to follow new studies for AMORPHOUS, EOSINOPHILIC, AND ACELLULAR DEPOSIT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Antibody therapy tested for Tough-to-Treat amyloidosis

Disease control Completed

This Phase 2 trial tested whether the antibody drug isatuximab could help control AL amyloidosis in patients whose disease had returned or didn't respond to prior treatments. The study enrolled 43 adults with confirmed organ damage from this rare protein disorder. Participants re…

Matched conditions: AMORPHOUS, EOSINOPHILIC, AND ACELLULAR DEPOSIT

Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

AMORPHOUS, EOSINOPHILIC, AND ACELLULAR DEPOSIT

Get alerted when new AMORPHOUS, EOSINOPHILIC, AND ACELLULAR DEPOSIT trials appear

Antibody therapy tested for Tough-to-Treat amyloidosis